Tenderwize
Zurück zur Suche

Eribulin (ATC: L01XX41)

AOK Nordost - Die Gesundheitskasse·Potsdam, Germany·Deadline Feb 21, 2027 · 180 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V für die KV-Region Berlin

70/100

Opportunity Score

PromisingLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

70 / 100

Komplexität

30 / 100

Risikofaktoren

Automatic contract termination if another regional/national discount contract for the same active substance enters into...

Short contract duration (max 9 months) and potential for early termination reduce planning certainty and may not justif...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Strong opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive discount agreements for oncological parenteral preparations from finished medicinal products
  • Active substance: Eribulin (ATC L01XX41)
Vollständige Zusammenfassung anzeigen

Open-House model for non-exclusive discount agreements under §130a Abs. 8c SGB V for oncology parenteral preparations in the Berlin region, open to all eligible pharmaceutical companies. One lot (Eribulin, ATC L01XX41). No selection competition – contracts awarded to all qualifying bidders. Rolling submission deadlines until 21.02.2027. No estimated value disclosed. Short contract duration (approx. 9 months).

Risiken

Automatic contract termination if another regional/national discount contract for the same active substance enters into...

Short contract duration (max 9 months) and potential for early termination reduce planning certainty and may not justif...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical company

Administrative

  • Submit signed contract in Schriftform (handwritten signature) in duplicate
  • Submit filled file 'OHV_8c_Berlin_Festlegung_[Wirkstoffname]_PZN' electronically via DTVP portal

Anforderungen können unvollständig sein.

Auftraggeber

Ort

Potsdam, DEU

Website

www.aok.de

Kennung

DE275390265

Tätigkeit

Health

Lose (1)

LOT-0001

Eribulin (ATC: L01XX41)

Non-exclusive discount agreement for Eribulin (ATC L01XX41) for parenteral preparations in oncology for the Berlin region. Open-House model, no selection. Contracts executed with all qualified pharmaceutical companies. Earliest start 01.08.2026, end 30.04.2027. Automatic termination if a comparable regional/national discount contract enters into force.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Jul 2026 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 21, 2027

Vergabedetails

Veröffentlichungsdatum
14 May 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
332623-2026

Dokumente (2)

Ähnliche Ausschreibungen